clinical trial · NCT03123848
A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants
Janssen Pharmaceutical K.K.·phase4·completed·n = 8
HealthyDarunavir/Cobicistat
brief summary
The purpose of the study is to evaluate the pharmacokinetic (PK) and safety of darunavir (DRV) and cobicistat (COBI) after a single oral administration of Prezcobix (DRV/COBI fixed-dose combination tablet) in healthy Japanese adult participants.
started
Apr 14, 2017
primary completion
May 19, 2017
completion
May 19, 2017
last updated
Feb 4, 2025
official title
An Open-label Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single-oral Administration of Darunavir/Cobicistat Fixed-Dose Combination Tablet in Healthy Japanese Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol